Research Review
11 min read
Melanotan Tanning Peptides: Risks and Research Evidence
Melanotan-1 and Melanotan-2 tanning peptide review — how they work, documented risks including mole changes, side effects, and legal status.
Peptide Protocol Wiki
approved
Afamelanotide
Also known as: Scenesse, Melanotan I, Melanotan-1, NDP-MSH, CUV1647
New to skin peptides?Browse all skin peptides →
📌TL;DR
- •Increases pain-free time in direct sunlight for EPP patients by stimulating protective eumelanin production
- •Subcutaneous implant provides sustained drug release over approximately 60 days, requiring only 5-6 treatments per year
- •Acceptable side-effect profile demonstrated across multiple Phase 3 trials
- •Also under investigation for vitiligo repigmentation and other photodermatoses
Community-Reported Side EffectsAnecdotal?
Protocol Quick-Reference
Erythropoietic protoporphyria (EPP) photoprotection
Dosing
Amount
16 mg implant
Frequency
Every 2 months
Duration
Seasonal (spring through fall)
Administration
Route
SCTiming
Administered by certified healthcare provider as a bioresorbable implant above the anterior supra-iliac crest. Typically 5-6 implants per year.
Cycle
Duration
Seasonal treatment (approximately 5-6 months)
Repeatable
Yes
⚗️ Suggested Bloodwork (3 tests)
Full-body skin examination
When: Before each implant
Why: Check for suspicious melanocytic lesions
CBC with differential
When: Baseline
Why: Baseline blood cell counts
Liver function tests
When: Baseline
Why: Baseline hepatic function assessment
💡 Key Considerations
- →FDA-approved prescription medication: must be administered by certified healthcare providers through the Scenesse REMS Program
- →Causes skin darkening (tanning) as an expected pharmacological effect
- →Does not provide protection against UV damage; sunscreen should still be used
Subscribe to unlock this content
Get weekly peptide research summaries, new study alerts, and protocol updates — free.
150+ peptide profiles · 30+ comparisons · 18 research tools
Already subscribed?
Scientific Details
- Molecular Formula
- C78H111N21O19
- Molecular Weight
- 1647 Da
- CAS Number
- 75921-69-6
- Sequence
- Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
What is Afamelanotide?#
Afamelanotide (marketed as Scenesse) is a synthetic tridecapeptide (13 amino acid) analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It was developed by Clinuvel Pharmaceuticals and received EMA approval in 2014 and FDA approval in October 2019 for increasing pain-free light exposure in adults with erythropoietic protoporphyria (EPP).
The drug is also known by its research designation [Nle4, D-Phe7]-alpha-MSH (NDP-MSH), which describes the two key amino acid substitutions that distinguish it from native alpha-MSH and confer enhanced potency and stability.
Mechanism of Action#
Afamelanotide acts as a potent and selective agonist of the melanocortin 1 receptor (MC1R), which is expressed on melanocytes in the skin. MC1R activation triggers:
- Eumelanin synthesis: Stimulates the production of eumelanin (brown-black melanin) rather than pheomelanin (red-yellow melanin), providing true photoprotection
- Melanin distribution: Promotes melanin granule transfer from melanocytes to surrounding keratinocytes
- Photoprotection: Eumelanin absorbs UV and visible light, providing a biological shield against phototoxic reactions
- Anti-inflammatory effects: MC1R activation has anti-inflammatory and antioxidant properties independent of melanogenesis
In EPP, where excess protoporphyrin IX causes severe phototoxic reactions to visible light, the increased eumelanin acts as a photoprotective barrier, allowing patients to tolerate light exposure that would otherwise cause excruciating pain.
Clinical Significance#
EPP affects approximately 1 in 75,000-200,000 people. Patients experience severe, immediate phototoxic pain upon exposure to visible light, which cannot be prevented by conventional sunscreens (which primarily block UV). Prior to afamelanotide, no pharmacological treatment existed, and patients were forced to severely restrict outdoor activities.
Important Considerations#
Afamelanotide is administered only in certified healthcare settings through a subcutaneous implant procedure. It is not available as a self-administered injection. The drug causes skin darkening (tanning) as an expected pharmacological effect. Skin examinations are recommended before and during treatment to monitor for melanocytic changes.
Key Research Findings#
Afamelanotide for Erythropoietic Protoporphyria, published in New England Journal of Medicine (Langendonk JG et al., 2015; PMID: 26132941):
Phase 3 multicenter, randomized, double-blind, placebo-controlled trial evaluating afamelanotide 16 mg subcutaneous implant in adults with EPP across US and European sites.
- Afamelanotide significantly increased pain-free time in direct sunlight
- Acceptable side-effect profile with no serious drug-related adverse events
- Improved quality of life measures related to outdoor activities
Long-Term Observational Study of Afamelanotide in 115 Patients with Erythropoietic Protoporphyria, published in British Journal of Dermatology (Biolcati G et al., 2015; PMID: 25494545):
Long-term observational study following 115 EPP patients treated with afamelanotide in Italy over multiple years.
- Sustained benefit with repeated treatment cycles
- Significant increase in sun exposure tolerance
- Favorable long-term safety profile
Related Reading#
Stay current on Afamelanotide research
We summarize new studies, safety updates, and dosing insights — delivered biweekly.
Community Protocols Available
See real-world usage patterns alongside the clinical evidence above. Community-sourced, not clinically verified.
Based on 30+ community reports
View community protocolsFrequently Asked Questions About Afamelanotide
What is afamelanotide (Scenesse)?
Afamelanotide is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that activates the MC1 receptor to stimulate eumelanin production in the skin. It is FDA-approved as a subcutaneous implant for adults with erythropoietic protoporphyria to increase pain-free light exposure.
How does afamelanotide differ from Melanotan II?
Afamelanotide (Melanotan I) is a 13-amino acid linear peptide that is relatively selective for MC1R. Melanotan II is a shorter cyclic peptide that activates multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R), causing additional effects including appetite suppression and sexual arousal. Afamelanotide is FDA-approved; Melanotan II is not.
What is erythropoietic protoporphyria?
EPP is a rare inherited disorder of heme biosynthesis caused by deficiency of ferrochelatase enzyme. Excess protoporphyrin IX accumulates in erythrocytes and skin, causing severe phototoxic pain upon exposure to visible light. Patients must severely limit sun exposure, significantly impacting quality of life.
Explore Further
Related Peptides
View all peptides →Skin & HairCosmetic & Anti-Wrinkle
Melanotan-1
Melanotan-1 (Afamelanotide): Approved alpha-MSH analog. Covers melanocortin mechanism, Scenesse for EPP, photoprotective tanning, and safety data.
Skin & HairReproductive Health
Melanotan-2
Melanotan-2: Cyclic melanocortin peptide for tanning and sexual function. Covers MC1R/MC4R activation, dosing protocols, side effects, and regulation.
Weight Loss & MetabolismHormonal Health
Setmelanotide (IMCIVREE)
Setmelanotide (IMCIVREE): FDA-approved MC4R agonist for rare genetic obesity due to POMC, PCSK1, or LEPR deficiency. First-in-class targeted therapy for monogenic obesity.
Cosmetic & Anti-WrinkleSkin & Hair
Argireline
Argireline (acetyl hexapeptide-8): topical SNARE complex inhibitor for dynamic wrinkle reduction. Up to 30% wrinkle depth improvement as a non-invasive Botox alternative.
⚠️
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.
Related Articles
You Might Also Like
Related content you may find interesting